Kada Mohammed Samia, Billa Oumar, Ladoire Sylvain, Jankowski Clementine, Desmoulins Isabelle, Poillot Marie-Laure, Coutant Charles, Beltjens Françoise, Dabakuyo Sandrine, Arnould Laurent
Department of Gynaecology and Obstetrics, Jean Verdier Hospital, Assistance Publique Des Hôpitaux de Paris (APHP), Avenue du 14 Juillet, 93140, Bondy, France.
Department of Epidemiology, Georges-François Leclerc Centre, 1 Rue du Professeur Marion, 21000, Dijon, France.
Breast Cancer. 2023 May;30(3):343-353. doi: 10.1007/s12282-022-01432-3. Epub 2023 Jan 30.
HER2-positive (HER2 +) invasive lobular breast cancer (ILC) is rare and poorly characterised. In particular, patient outcomes compared to those associated with HER2 + invasive ductal cancer (IDC) and HER2-negative (HER2 -) ILC, as well as the benefits of anti-HER2 therapy, are not well established.
We analysed the data from the Côte d'Or Registry of Breast and Gynaecological Cancers (France) for all patients diagnosed with early-stage HER2 + ILC (62 cases), HER2 + IDC (833 cases) and HER2 - ILC (685 cases) between 1998 and 2015 to compare overall and disease-free survival (OS and DFS) between these groups in correlation with anti-HER2 therapy.
ILCs were associated with older age, larger tumours, lower histological grades, higher hormonal receptor positivity rates and multifocality, and more common endocrine therapy. OS and DFS between the three groups did not differ. We found that anti-HER2 therapy was associated with a survival benefit in patients with HER2 + IDC. In contrast, the survival of HER2 + ILC patients was not improved by anti-HER2 treatment, remaining close to that of HER2 - ILC patients.
HER2 + ILC seems not to be associated with better outcomes than HER2 + IDC but may not differ from HER2 - ILC in terms of survival.
人表皮生长因子受体2阳性（HER2 +）浸润性小叶癌（ILC）较为罕见，且特征描述不足。特别是，与HER2 +浸润性导管癌（IDC）和HER2阴性（HER2 -）ILC相比，患者的预后以及抗HER2治疗的益处尚未明确。
我们分析了法国科多尔省乳腺癌和妇科癌症登记处的数据，这些数据来自1998年至2015年间所有被诊断为早期HER2 + ILC（62例）、HER2 + IDC（833例）和HER2 - ILC（685例）的患者，以比较这些组之间的总生存期和无病生存期（OS和DFS），并与抗HER2治疗相关联。
ILC与年龄较大、肿瘤较大、组织学分级较低、激素受体阳性率较高、多灶性以及更常见的内分泌治疗相关。三组之间的OS和DFS没有差异。我们发现抗HER2治疗与HER2 + IDC患者的生存获益相关。相比之下，抗HER2治疗并未改善HER2 + ILC患者的生存，其生存情况仍接近HER2 - ILC患者。
HER2 + ILC似乎并不比HER2 + IDC有更好的预后，但在生存方面可能与HER2 - ILC没有差异。
